Please assess the completion status of the following clinical trial:

Trial Title: The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patients undergoing an arthroscopic shoulder procedure (rotator cuff repair, decompression, labrum repair)~* Patients ages 18-75, inclusive~* Female patients must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly~* Male patients must be using an effective form of contraception~Exclusion Criteria~* Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)~* Younger than 18 years of age~* Older than 75 years of age~* Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners~* History of cannabis abuse or dependence~* History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values~* History of stroke or acute coronary syndromes within 3 months before surgery~* Abnormal coagulation profile~* Renal failure (serum creatinine \> 250 μmol/L \[2.83 mg/dL\]) or liver cirrhosis~* Patients with a history of hypersensitivity to Percocet~* Patients that have been on pre-operative opioid management for any reason~* Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder~* Patients diagnosed with major depression, psychosis, or substance abuse disorder~* Patients with current or a history of suicidal ideation~* Breastfeeding females~* Patients with clinically significant illness, including cardiovascular disorders~* Clinically significant lab abnormalities~* Abnormal LFTs~* Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures~* Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).~* Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 (listed below) concomitantly~* Patients taking strong CYP3A4 and CYP2C19 inducers (listed below) concomitantly~* Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 (listed below) concomitantly

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - CBD (Type: EXPERIMENTAL): None
- Cohort 2 - Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).